Literature DB >> 18723683

Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.

Ailin Bai1, Eileen Higham, Herman N Eisen, K Dane Wittrup, Jianzhu Chen.   

Abstract

To study T cell responses to tumors in an autochthonous model, we expressed a CD8 T cell epitope SIYRYYGL (SIY) in the prostate of transgenic adenocarcinoma (TRAMP) mice (referred to as TRP-SIY), which spontaneously develop prostate cancer. Naïve SIY-specific CD8 T cells adoptively transferred into TRP-SIY mice became tolerized in the prostate draining lymph nodes. Vaccination of TRP-SIY mice intranasally with influenza virus that expresses the SIY epitope resulted in generation of SIY-specific effector T cells in the lung-draining lymph nodes. These effector T cells expressed TNFalpha and IFNgamma, eliminated SIY peptide-loaded target cells in vivo, and infiltrated prostate tumors, where they rapidly lost the ability to produce effector cytokines. A population of these T cells persisted in prostate tumors but not in lymphoid organs and could be induced to re-express effector functions following cytokine treatment in vitro. These findings suggest that T cells of a given clone can be activated and tolerized simultaneously in different microenvironments of the same host and that effector T cells are rapidly tolerized in the tumors. Our model provides a system to study T cell-tumor interactions in detail and to test the efficacy of cancer immunotherapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723683      PMCID: PMC2519043          DOI: 10.1073/pnas.0805599105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  A model T-cell receptor system for studying memory T-cell development.

Authors:  Jianzhu Chen; Herman N Eisen; David M Kranz
Journal:  Microbes Infect       Date:  2003-03       Impact factor: 2.700

Review 2.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 3.  Cancer immunotherapy: a treatment for the masses.

Authors:  Joseph N Blattman; Philip D Greenberg
Journal:  Science       Date:  2004-07-09       Impact factor: 47.728

4.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

Review 5.  Manipulation of costimulatory signals to enhance antitumor T-cell responses.

Authors:  J P Allison; A A Hurwitz; D R Leach
Journal:  Curr Opin Immunol       Date:  1995-10       Impact factor: 7.486

6.  Prostate cancer in a transgenic mouse.

Authors:  N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

7.  A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL.

Authors:  Michael A Lyman; Sandra Aung; Judith A Biggs; Linda A Sherman
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

8.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Authors:  C G Clemente; M C Mihm; R Bufalino; S Zurrida; P Collini; N Cascinelli
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

Review 9.  Animal models of tumor immunity, immunotherapy and cancer vaccines.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Curr Opin Immunol       Date:  2004-04       Impact factor: 7.486

Review 10.  Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

View more
  45 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles.

Authors:  Matthias T Stephan; Sirkka B Stephan; Peter Bak; Jianzhu Chen; Darrell J Irvine
Journal:  Biomaterials       Date:  2012-05-15       Impact factor: 12.479

3.  T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine.

Authors:  Moses K Donkor; Abira Sarkar; Peter A Savage; Ruth A Franklin; Linda K Johnson; Achim A Jungbluth; James P Allison; Ming O Li
Journal:  Immunity       Date:  2011-07-14       Impact factor: 31.745

4.  Overcoming obstacles to the effective immunotherapy of human cancer.

Authors:  Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

5.  High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.

Authors:  Andrew G Brandmaier; Wolfgang W Leitner; Sung P Ha; John Sidney; Nicholas P Restifo; Christopher E Touloukian
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

6.  Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Authors:  David C Binder; Boris Engels; Ainhoa Arina; Ping Yu; James M Slauch; Yang-Xin Fu; Theodore Karrison; Byron Burnette; Christian Idel; Ming Zhao; Robert M Hoffman; David H Munn; Donald A Rowley; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

7.  Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3.

Authors:  Jason Brayer; Fengdong Cheng; Hongwei Wang; Pedro Horna; Ildefonso Vicente-Suarez; Javier Pinilla-Ibarz; Eduardo M Sotomayor
Journal:  Immunol Lett       Date:  2010-03-25       Impact factor: 3.685

8.  CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Authors:  S Peter Bak; Mike Stein Barnkob; K Dane Wittrup; Jianzhu Chen
Journal:  Cancer Immunol Res       Date:  2013-09-20       Impact factor: 11.151

9.  Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.

Authors:  Lindsay K Ward-Kavanagh; Junjia Zhu; Timothy K Cooper; Todd D Schell
Journal:  Cancer Immunol Res       Date:  2014-05-06       Impact factor: 11.151

10.  Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

Authors:  Haiyan Xiao; Yibing Peng; Yuan Hong; Lei Huang; Z Sheng Guo; David L Bartlett; Ning Fu; David H Munn; Andrew Mellor; Yukai He
Journal:  J Immunol       Date:  2013-04-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.